Episode 122 - Todd Zavodnick - CEO of Excellergy

🎙 New Episode Live – Todd Zavodnick, CEO of Excellergy

Todd Zavodnick is the CEO of Excellergy, a clinical-stage biotechnology company redefining allergy treatment. Their mission? To make therapies faster, more effective, and far more convenient for patients — transforming the experience of managing allergies.

Before Excellergy, Todd built a track record of leadership in biotech, bringing together scientific rigor and strategic vision to tackle complex challenges in patient care.

In this episode, we discuss:

• Excellergy’s approach to improving existing allergy therapies and what sets them apart in the field.

• Clinical milestones, including their Phase 1 launch in Australia and plans for Phase 2 next year.

• The patient impact — how Excellergy is aiming to reduce wait times and make treatment truly transformative.

Whether you’re interested in biotech innovation, clinical development, or patient-centric therapies, this conversation is packed with insight.